Skip to content

Cervical Cancer Health Center

Medical Reference Related to Cervical Cancer

  1. Cervical Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Questions or Comments About This Summary

    If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

  2. Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary

    If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.

  3. Cervical Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?

    Cancer prevention is action taken to lower the chance of getting cancer. By preventing cancer,the number of new cases of cancer in a group or population is lowered. Hopefully,this will lower the number of deaths caused by cancer. To prevent new cancers from starting,scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a ...

  4. Cervical Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Cervical Cancer

    Recurrent cervical cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the cervix or in other parts of the body.

  5. Uterine Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Uterine Sarcoma

    There is currently no standard therapy for patients with recurrent disease. These patients should be entered into an ongoing clinical trial. Patients who present with uterine sarcoma have been treated on a series of phase II studies by the Gynecologic Oncology Group, including the GOG-87B trial, for example. These chemotherapy studies have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide. These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. As an example, in patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[1] a 33% response rate in patients with endometrial stromal cell sarcomas,[2] and a 17.2% partial response rate in patients with leiomyosarcomas.[3] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for recurrent disease.[4,5] Cisplatin has

  6. Cervical Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Cervical Cancer

    Standard treatments for patients with cervical cancer include:Surgery.Radiation therapy.Chemotherapy.Five randomized, phase III trials (GOG-85, RTOG-9001, GOG-120, GOG-123, and SWOG-8797) have shown an overall survival advantage for cisplatin-based therapy given concurrently with radiation therapy,[1,2,3,4,5,6] while one trial examining this regimen demonstrated no benefit.[7] The patient populations in these studies included women with Féderation Internationale de Gynécologie et d'Obstétrique (FIGO) stages IB2 to IVA cervical cancer treated with primary radiation therapy and women with FIGO stages I to IIA disease found to have poor prognostic factors (metastatic disease in pelvic lymph nodes, parametrial disease, or positive surgical margins) at the time of primary surgery. Although the positive trials vary in terms of the stage of disease, dose of radiation, and schedule of cisplatin and radiation, the trials demonstrate significant survival benefit for this combined approach.

  7. Cervical Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - nci_ncicdr0000062756-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Screening

  8. Cervical Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - nci_ncicdr0000062817-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Cervical Cancer Prevention

  9. Endometrial Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Endometrial Cancer

    The most common endometrial cancer cell type is endometrioid adenocarcinoma, which is composed of malignant glandular epithelial elements; an admixture of squamous metaplasia is not uncommon. Adenosquamous tumors contain malignant elements of both glandular and squamous epithelium;[1] clear cell and papillary serous carcinoma of the endometrium are tumors that are histologically similar to those noted in the ovary and the fallopian tube, and the prognosis is worse for these tumors.[2] Mucinous, squamous, and undifferentiated tumors are rarely encountered. Frequency of endometrial cancer cell types is as follows: Endometrioid (75%–80%). Ciliated adenocarcinoma.Secretory adenocarcinoma.Papillary or villoglandular.Adenocarcinoma with squamous differentiation.Adenoacanthoma.Adenosquamous.Uterine papillary serous (<10%).Mucinous (1%).Clear cell (4%).Squamous cell (<1%).Mixed (10%).Undifferentiated.References: Zaino RJ, Kurman R, Herbold D, et al.: The significance of squamous

  10. Cervical Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

Displaying 91 - 100 of 159 Articles << Prev Page 6 7 8 9 10 11 12 13 14 15 Next >>

Today on WebMD

cancer cell
HPV is the top cause. Find out more.
doctor and patient
Get to know the Symptoms.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
what is your cancer risk
HEALTH CHECK